| EGFR inhibitor |
Erlotinib |
Advanced EGFR mutation-positive NSCLC |
(77,78) |
| Gefitinib |
Advanced NSCLC
patients harboring activating EGFR mutations |
(79,80) |
| Cetuximab |
Advanced NSCLC |
(81) |
| Osimertinib |
NSCLC harboring a common EGFR
mutation |
(82,83) |
| Necitumumab |
Advanced squamous
nonsmall-cell lung cancer |
(84,85) |
| Dacomitinib |
Patients with
advanced EGFR mutation-positive nonsmall-cell
lung cancer |
(86,87) |
| EGFR/HER2 inhibitor |
Afatinib |
First-line therapy of EGFR mutant NSCLC patients
and metastatic NSCLC whose tumors have nonresistant EGFR
|
(88−90) |
| ALK/ROS1 inhibitor |
Crizotinib |
Advanced ALK-positive NSCLC and patients
with ROS1-rearranged
advanced nonsmall-cell lung cancer (NSCLC) |
(14,91,92) |
| Lorlatinib |
Patients with ALK-positive advanced
NSCLC and ROS1-positive
advanced/metastatic NSCLC |
(62,92) |
| ALK inhibitor |
Ceritinib |
Advanced ALK-rearranged NSCLC |
(93,94) |
| Alectinib |
Patients with ALK-positive advanced/metastatic
NSCLC |
(95,96) |
| Brigatinib |
Patients with ALK-positive advanced/metastatic
NSCLC |
(97,98) |
| VEGF-A inhibitor |
Bevacizumab |
Patients with unresectable or metastatic nonsquamous NSCLC |
(99,100) |
| Ramucirumab |
Patients with
NSCLC with disease progression or after platinum-based
chemotherapy |
(101,102) |
| VEGFR/FGFR/PDGFR inhibitor |
Nintedanib |
Advanced NSCLC |
(103,104) |
| mTOR inhibitor |
Everolimus |
Advanced NSCLC |
(105,106) |
| BRAF
inhibitor |
Dabrafenib |
NSCLC harboring BRAF
mutation |
(107,108) |
| MEK inhibitor |
Trametinib |
NSCLC harboring KRAS mutation |
(109,110) |
| PD-1 inhibitor |
Nivolumab |
Advanced squamous and nonsquamous NSCLC with
progression or
after platinum-based chemotherapy and patients with recurrent SCLC |
(111−113) |
| Pembrolizumab |
Advanced squamous
and nonsquamous NSCLC with progression or
after platinum-based chemotherapy |
(112,114,115) |
| PD-L1 inhibitor |
Atezolizumab |
Metastatic nonsquamous NSCLC and PD-L1-positive NSCLC that
progressed during or after standard treatments |
(112,116,117) |
| Durvalumab |
Locally advanced NSCLC |
(112,118) |
